The direct primary care revolution
A small but growing group of primary care doctors are saying, "no more" to EHR requirements, useless quality measures, and indecipherable bills. More
What’s the harm in earlier screening for colorectal cancer?
Cancer advocacy groups are cheering the new screening guidelines for colorectal cancer, but few reports have examined both the costs and benefits of lowering the age of screening. More
The CABANA trial: Another cardiac procedure bites the dust?
Catheter ablation for atrial fibrillation has been used for 20 years, and grown into a $4.5 billion industry. But is the procedure actually effective? More
Slow progress in reducing breast cancer overscreening
American women are still getting too many mammograms. Despite recommendations from the US Preventive Services Task Force and the American Cancer Society against routine screening for breast cancer before age 50, the rates of mammogram screening have not changed significantly in the past ten years. In a recent JAMA Clinical Update, Dr. Nancy Keating and […] More
When doing everything means doing less
For Randi Oster, the hardest part of her father's cancer wasn't getting him through treatment. It was getting his doctors to listen to what he wanted. More
The cart is driving the horse: Misguided performance measures
When it comes to measuring quality, there is a huge disconnect between payers and physicians. A recent analysis in the New England Journal of Medicine lends support to the physicians' side of the issue. More
Belief and evidence: How framing health news matters
Gina Kolata misrepresents the debate on tPA for strokes by painting the issue as evidence versus belief. More
What we know and don’t know about overdiagnosis
A study in The BMJ shows that overdiagnosis research is growing but discrepancies in definitions and measurement complicate the evidence. More
What’s the harm in excessive cancer screening?
Not only does too much cancer screening lead to false positives and overtreatment, it can also skew our data. More
Has “Less is More” gone too far? The New England Journal says it has.
Are we oversimplifying the discussion when it comes to overuse? In a NEJM editorial, Lisa Rosenbaum argues that "less is more" can be a slippery slope. Here's what we thought about her controversial piece. More
As dangerous as opioids: Benzo overprescription becoming a crisis
Opioids aren't the only drug being dangerously overprescribed... More
New blood pressure guidelines increases danger of overtreatment
Why the new lower blood pressure target could be harmful to patients... More
Can one study change clinical practice?
Professor Doug McKell explains why ORBITA might not be enough to reduce unnecessary stents. More
HPV protection or cancer vaccine? Putting Gardasil in context
Why was Gardasil originally marketed as a cervical cancer vaccine? Professor Samantha Gottlieb explains. More
INTERVIEW: Dr. David Brown on startling stent study
Cardiologist David Brown addresses some of the criticisms of the controversial ORBITA trial. More
Value-based care initiatives floundering in a broken system
Does value-based care stand a chance against the fee-for-service Goliath? More
Lown president, cardiologist, reacts to stent controversy
A study in The Lancet this week has rocked the world of cardiology by showing that stents are no better than a placebo in relieving chest pain. More
Health care? More like health scare!
Every day is Halloween for pharma marketers... More
Navigating the mess of medical misinformation
Why is clinical research such a mess? And how can we clean it up? More
Is there a middle ground in the statin debate?
How do we balance evidence and patient preferences in the intensifying statin debate? More